Active Autophagy Suppression Functions as a Protective Sequestration Mechanism for Protein Aggregates in Aging

Hypothesis

In aged cells, the upregulation of autophagy inhibitors such as Rubicon does not simply reflect a breakdown of cleanup machinery. Instead, it actively sequesters toxic protein aggregates into long‑lived, autophagy‑derived compartments that act as inert depots. By locking aggregates inside these vesicles, the cell prevents their release, templated seeding, and subsequent spread to neighboring cells or extracellular space. This suppression is therefore a protective trade‑off: tolerating intracellular storage avoids the greater danger of propagating proteopathic strains throughout tissue.

Mechanistic Rationale

• Aggregate sequestration: During aging, misfolded proteins (e.g., α‑synuclein, tau) are preferentially captured by nascent autophagosomes. Rubicon‑mediated inhibition of VPS34 stalls autophagosome maturation, converting these vesicles into stable, lysosome‑resistant storage bodies.
• Consequences of premature activation: Forced autophagic flux (via Rubicon knockdown or mTORC1 inhibition) would disrupt these depots, liberating aggregates that can act as seeds for further misfolding and trigger inflammasome activation through extracellular danger signals.
• Feedback to senescence: Persistent aggregate retention reduces cytosolic stress signaling, delaying the onset of senescence‑associated secretory phenotype (SASP). Conversely, acute aggregate release accelerates senescence, as shown by autophagy‑deficient cardiomyocytes adopting a senescent state [5].
• Tissue specificity: In adipocytes, declining Rubicon leads to excessive autophagy that degrades PPARγ coactivators, causing fat atrophy [6]. This illustrates that the set point of autophagic activity must be tuned to the aggregate burden and metabolic needs of each tissue.

Testable Predictions

1. Biochemical: In aged mouse brain, fractionation will reveal a Rubicon‑enriched, lipid‑positive vesicle fraction that contains high molecular weight α‑synuclein/tau and is resistant to protease K digestion unless lysates are treated with detergents that disrupt membranes.
2. Genetic: Neuron‑specific Rubicon knockdown in aged mice will increase soluble oligomer levels in the interstitial fluid (measured by microdialysis) and accelerate the spread of pathology to connected regions, worsening motor deficits despite elevated LC3‑II conversion.
3. Pharmacological: Transient treatment with a lysosomal stabilizer (e.g., chloroquine at low dose) in aged Rubicon‑knockout animals will rescue the deleterious phenotype by re‑sequestering liberated aggregates, confirming that toxicity stems from aggregate release rather than autophagy loss per se.
4. Immunological: Blocking extracellular aggregate seeding with antibodies against α‑synuclein will mitigate the exacerbation of neurodegeneration seen after Rubicon inhibition, linking the harmful effect to intercellular transmission.

Falsifiability

If Rubicon depletion in aged tissue does not increase extracellular detectable aggregates, does not accelerate pathology spread, or does not worsen functional outcomes, the hypothesis that autophagy suppression serves a protective sequestration role would be refuted. Likewise, if enhancing autophagy flux uniformly improves aged phenotypes without exacerbating aggregate dissemination, the protective depot model would need revision.

Implications

Reframing autophagy inhibition as an adaptive, aggregate‑containment strategy shifts therapeutic focus from indiscriminate activation of the pathway to modulating the stability of autophagosome‑derived storage vesicles. Interventions that enhance vesicle integrity or promote safe aggregate degradation—rather than simply increasing flux—may preserve the beneficial sequestration while allowing eventual clearance.